The team behind docjo: Dr. Ulrich Muehlner, Co-Founder & Business Director; Jochen Bohner, Finance & International Expansion Director; Oliver Felix, Co-Founder & CEO; Lukas Gamper, CTO; Dr. med. Yves Nordmann, Co-Founder & Medical Director
Monday, June 23, 2025
Reading Time: 6 min
Transforming chronic care: why docjo is opening its funding round to the crowd
Chronic diseases account for 90% of global healthcare costs, yet most patients feel unsupported and many physicians are experiencing burnout. At the intersection of medical need and technological innovation, docjo is reshaping how chronic conditions are treated. With CE-certified digital therapies already validated in clinical studies, the company is entering a new phase of growth and inviting a broader community to be part of it.
We sat down with docjo-CEO Oliver Felix to learn why they are raising part of their current round via OOMNIUM, what sets their platform apart, and why now is the time to invest in the future of chronic care.
OOMNIUM: Why did you decide to raise part of your funding round through OOMNIUM with minority shareholders?
Oliver Felix: We see the OOMNIUM campaign as a strong strategic complement to our ongoing financing round. docjo is in a highly attractive growth phase, with CE-certified products backed by clinical data, a scalable business model, and a clear revenue perspective. With OOMNIUM, we can broaden our investor base in a targeted way—reaching people who are not only willing to invest capital but also want to become ambassadors of our vision. Some of them may even be personally or familiarly affected by chronic diseases and want to be part of this transformation in healthcare.
OOMNIUM gives investors early access to a scalable, regulation-compliant HealthTech company—with measurable impact and a clear exit perspective.
For investors, this presents a rare opportunity: docjo is addressing a market with immense unmet needs and billion-dollar potential. Chronic diseases are responsible for enormous healthcare costs. At the same time, we are witnessing a profound shift in the healthcare system: software is becoming the new therapy—regulated, prescribable, and reimbursable. docjo is at the heart of this paradigm shift. In short: we combine social relevance with economic substance and attractive returns. OOMNIUM gives investors early access to a scalable, regulation-compliant HealthTech company—with measurable impact and a clear exit perspective.
OOMNIUM: What problem does docjo solve?
Oliver Felix: 90% of patients with chronic illnesses feel unsupported. Many don't understand their condition, don’t know how to manage it, and miss preventive checkups. On the other side, 60% of physicians report symptoms of burnout. They lack time, actionable patient data, and continuity of care. Meanwhile, 90% of global healthcare costs are caused by chronic diseases. The system is overwhelmed, and that's not sustainable.
But it’s fixable—and that’s exactly what docjo is doing. Our solution is a software-based platform for treating chronic diseases. This is not another wellness app—it’s certified digital medicine. We follow a scientifically validated four-pillar model: (1) education and awareness, (2) analysis and insights, (3) direct interventions, and (4) indirect interventions. This approach allows us to continuously support patients and help physicians make better decisions. The result: improved health outcomes. Our products are CE-certified, easily adaptable to various diseases, and have already been used in six clinical studies in collaboration with leading institutes, university hospitals, and well-known industry partners.
This is not another wellness app—it’s certified digital medicine.
OOMNIUM: What does this look like in practice?
Oliver Felix:: Take a patient with asthma—our product Velaria becomes her digital companion. It provides personalized feedback based on symptom trends, pollen levels, and key medical metrics like the ACT score (Asthma Control Test). Velaria encourages proper breathing, medication adherence, and patient engagement. At the same time, it generates a structured report for the physician, offering a clear and efficient overview of the patient’s condition. This saves valuable consultation time and improves the quality of care.
This isn’t just about patient engagement—it’s about measurable behavior change, therapy adherence, and clinical outcomes. What makes us unique is that we integrate into the real-world treatment of chronically ill patients. We collaborate with doctors and align with clinical workflows—from intake and medical history to feedback loops and shared decision-making. Our structured tools make the doctor-patient dialogue more efficient, data-driven, and informed. That’s why interest from physicians and healthcare systems is so high. Our products are CE-certified and ISO-compliant, providing the regulatory foundation and necessary quality assurance.
What happened in fintech and mobility is now happening in healthcare.
OOMNIUM: What makes you confident that your product will succeed?
Oliver Felix: We're experiencing a fundamental shift in healthcare: Digital Health is no longer a fringe concept—it’s becoming mainstream. There are now prescription-based digital therapies that are reimbursed, regulated, and even replacing traditional treatments like pharmaceuticals. Software is emerging as an equivalent—or even superior—form of medicine. What happened in fintech and mobility is now happening in healthcare.
On top of that, we have a truly unique, interdisciplinary, and highly experienced team with deep expertise in Digital Health, regulation, international commercialization, AI, and product development. We’ve proven multiple times that we can turn plans into reality—combining strong medical knowledge and excellent products with real market experience. Our solutions are not only clinically validated but also usable, scalable, and commercially viable. We understand healthcare systems, their stakeholders—and just as importantly—how to integrate with them and build partnerships that create real value.
OMMNIUM: Why is docjo an attractive investment opportunity for OOMNIUM investors?
Oliver Felix: docjo combines social impact with economic opportunity. We improve care for millions of people living with chronic conditions while offering a highly attractive investment opportunity in a billion-dollar market. Our solution is CE-certified, clinically validated, market-ready, and primed for scale. We have strategic partnerships and a clear business model with multiple revenue streams. Our pre-money valuation is CHF 6 million, with an expected ROI of 13–19x.
docjo operates in a fast-growing market driven by global megatrends: the rise of chronic diseases, shortage of healthcare professionals, shift toward value-based care, and ongoing digitalization. Investing in docjo means backing a strong team, a scalable digital platform model, and a globally growing market—while contributing to a sustainable improvement in chronic care.
OOMNIUM: Where do you see docjo in five years?
Oliver Felix: In five years, docjo will be one of the leading digital solutions for chronic care in Europe, with further expansion into international markets such as Brazil, the Gulf region, and other selected countries. Our platform will be successfully used across multiple disease areas—including respiratory, cardiovascular, and metabolic disorders—and will be a core component of hybrid care models (physician-guided, digital care pathways).
Together with partners in pharma, insurance, and healthcare, we will enable a new standard of care: continuous, data-driven, and patient-centered. Financially, we aim to reach break-even by 2027. In the following years, we are targeting an exit via acquisition by a strategic player in healthcare (e.g. pharma, medtech) or a HealthTech IPO.
Our goal is clear: in five years, docjo will be a major provider in the rapidly growing field of digital chronic care—backed by proven technology, regulatory maturity, quality, and a scalable business model.
What does docjo lead investor Dr. Dirk Kreder, Chairman and Founder of ALOM Ventures, say:
«As someone who has worked for over 25 years at the intersection of biotech, medtech, and pharma across the US, Europe, and Asia, I’ve seen many digital health ventures come and go. What made me decide to invest in docjo is not just the strength of their business case – it’s the rare combination of experience, integrity, and purpose behind it.The team is one of the most accomplished I’ve encountered at this stage: leadership roles at Novartis, founders of WellDoc and Oviva, deep roots in health insurance and scalable digital innovation. But what struck me even more was the quality of the conversations – honest, focused, and truly mission-driven.
«It’s a team that has already proven it can build, scale, and deliver real impact.»
I immediately felt a strong alignment with their vision of treating chronic diseases not in isolation, but in a holistic, integrated way that benefits patients, doctors, and healthcare systems alike. This isn’t just a company with potential – it’s a team that has already proven it can build, scale, and deliver real impact.That’s why I invested. Because I believe in the mission – and even more so in the people who are bringing it to life.»